Microbot Medical (MBOT) has provided an update.
Microbot Medical Inc. announced the completion of its first patient procedure using the LIBERTY® Endovascular Robotic Surgical System at Baptist Hospital of Miami, marking a significant milestone in its pivotal human clinical trial. The success of this trial is expected to pave the way for FDA submission and eventual commercialization. However, the company cautions that these forward-looking statements are subject to various factors and uncertainties, and there’s no guarantee that the trial’s outcomes will match their expectations. Investors are advised to consider the associated risks and ongoing disclosures filed with the SEC.
Learn more about MBOT stock on TipRanks’ Stock Analysis page.
